Biointron x SelectScience Webinar: Advancing AI-driven antibody discovery through experimental validation with RushDATA™

When

Thursday, November 19, 2026 at 11:00 AM ET | 8:00 AM PT

Register now >>

About

AI is accelerating antibody design, allowing teams to generate and optimize candidates at unprecedented speed and scale. But every computationally designed sequence still requires reliable experimental evidence to determine whether it expresses efficiently, binds as intended, and has the properties needed for further development.

In this webinar, Brady Wu, PhD, Head of Protein Center at Biointron, will explore how antibody discovery is evolving from traditional hybridoma approaches toward single B-cell technologies and AI-driven de novo design. He will examine why rapid, standardized wet-lab data is essential to candidate validation, model refinement, and a faster Design-Build-Test-Learn cycle.

Dr. Wu will also introduce RushData and discuss how rapid CHO expression, high-throughput characterization, and structured data can help teams evaluate antibody candidates more efficiently. The session will consider how these workflows can support increasingly complex modalities, including multispecific antibodies and antibody-drug conjugates.

Learn more here: https://www.biointron.com/rushdata

Register for the webinar >>

About the Speaker

Brady Wu, PhD, Head of Protein Center at Biointron

Dr. Brady Wu is a multidisciplinary scientist and biotech leader. He holds a Ph.D. in Chemistry from The Ohio State University (2007–2013), where he pioneered solid-state NMR studies of amyloid fibril dynamics, and a Peking University honors B.S. in Biology (2003–2007). At GenScript (2013–2021), he led 100+ teams in recombinant protein production service and global project management. As the Founding CEO of Solvo Biotherapeutics (2022–2024), he built China’s top cell-free protein synthesis platform with a 15+ team. Now leading the Protein Science group at Biointron (2024–present), he drives ADC conjugation, developability assessment, and recombinant protein/antibody R&D efforts in the company.

Register now >>